Erratum to: A novel neutralizing monoclonal antibody targeting the n-terminal domain of the mers-cov spike protein (Emerging Microbes & Infections (2017) 6, e60, 10.1038/emi.2017.18);A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

Emerging Microbes and Infections

Volumn 6, Issue 5, 2017, Pages

  Chen, Yingzhu ^a,b   Lu, Shuai ^b   Jia, Hao ^a,b   Deng, Yao ^b   Zhou, Jianfang ^b   Huang, Baoying ^b   Yu, Yueyang ^b   Lan, Jiaming ^b   Wang, Wenling ^b   Lou, Yongliang ^a   Qin, Kun ^b   Tan, Wenjie ^a,b  

^a School of Laboratory Medicine and Life Science   (China)

^b National Institute for Viral Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1B5; MONOCLONAL ANTIBODY 1F4; MONOCLONAL ANTIBODY 2B4; MONOCLONAL ANTIBODY 3A2; MONOCLONAL ANTIBODY 4A6; MONOCLONAL ANTIBODY 4C5; MONOCLONAL ANTIBODY 4F8; MONOCLONAL ANTIBODY 5F9; MONOCLONAL ANTIBODY 7D7; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; CORONAVIRUS SPIKE GLYCOPROTEIN; PROTEIN BINDING; VIRUS ANTIBODY; VIRUS RECEPTOR; VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EPITOPE MAPPING; FEMALE; IC50; IN VITRO STUDY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING DOMAIN; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS STRAIN; WILD TYPE; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; CORONAVIRUS INFECTION; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MOLECULAR MODEL; VERO CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CORONAVIRUS INFECTIONS; HUMANS; IMMUNIZATION; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, VIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VERO CELLS; VIRAL VACCINES;

EID: 85019596455     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2017.50     Document Type: Erratum

References (50)

1. Zaki AM, van Boheemen S, Bestebroer TM et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814-1820.
2. Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the 'knowns' and 'unknowns'. J Formos Med Assoc 2013; 112: 372-381.
3. Chan JF,Li KS,To KK et al. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 2012; 65: 477-489.
4. Ki M. 2015 MERS outbreak in Korea: hospital-to-hospital transmission. Epidemiol Health 2015; 37: e2015033.
5. Lee SS, Wong NS. Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea. Int J Infect Dis 2015; 38: 65-67.
6. Briese T, Mishra N, Jain K et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through wholegenome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio 2014; 5: e01146-01114.
7. Haagmans BL, Al Dhahiry SH, Reusken CB et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014; 14: 140-145.
8. Yusof MF, Eltahir YM, Serhan WS et al. Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates. Virus Genes 2015; 50: 509-513.
9. Health Protection Agency (HPA) UK Novel Coronavirus Investigation team. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 2013; 18: 20427.
10. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 2013; 369: 884-886.
11. Assiri A, McGeer A, Perl TM et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369: 407-416.
12. Seo YB, Heo JY, Song M-S et al. Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea. Clin Infect Dis 2015; 62: 755-760.
13. Cotten M, Lam TT, Watson SJ et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 2013; 19: 736-742B.
14. Chan JF, Lau SK, To KK et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015; 28: 465-522.
15. van Boheemen S, de Graaf M, Lauber C et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3: e00473-00412.
16. Lu G, Hu Y, Wang Q et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500: 227-231.
17. Wang N, Shi X, Jiang L et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23: 986-993.
18. Kirchdoerfer RN, Cottrell CA, Wang N et al. Pre-fusion structure of a human coronavirus spike protein. Nature 2016; 531: 118-121.
19. Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci USA 2014; 111: 15214-15219.
20. Jiang L,Wang N, Zuo T et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014; 6: 234ra259-234ra259.
21. Ying T, Du L, Ju TW et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014; 88: 7796-7805.
22. Tang X-C, Agnihothram SS, Jiao Y et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 2014; 111: E2018-E2026.
23. Li Y, Wan Y, Liu P et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 2015; 25: 1237-1249.
24. Corti D, Zhao J, Pedotti M et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA 2015; 112: 10473-10478.
25. Du L, Zhao G, Yang Y et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014; 88: 7045-7053.
26. Pascal KE, Coleman CM, Mujica AO et al. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA 2015; 112: 8738-8743.
27. Wang L, Shi W, Joyce MG et al. Evaluation of candidate vaccine approaches for MERSCoV. Nat Commun 2015; 6: 7712.
28. Lan J, Yao Y, Deng Y et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2015; 2: 1438-1446.
29. Du L, Kou Z, Ma C et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PloS One 2013; 8: e81587.
30. Ma C, Li Y, Wang L et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32: 2100-2108.
31. Tang J, Zhang N, Tao X et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 2015; 11: 1244-1250.
32. Zhang N, Tang J, Lu L et al. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res 2015; 202: 151-159.
33. Du L, Zhao G, Kou Z et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 87: 9939-9942.
34. Jiang S, Lu L, Du L et al. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect 2013; 66: 464-466.
35. Mou H, Raj VS, van Kuppeveld FJ et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013; 87: 9379-9383.
36. Yang Y, Du L, Liu C et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci USA 2014; 111: 12516-12521.
37. Raj VS, Mou H, Smits SL et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495: 251-254.
38. Ma C, Wang L, Tao X et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments - the importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32: 6170-6176.
39. Jiang S, Lu L, Du L et al. Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. J Infect 2013; 67: 156.
40. Chen Y, Rajashankar KR, Yang Y et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol 2013; 87: 10777-10783.
41. Peng G, Sun D, Rajashankar KR et al. Crystal structure of mouse coronavirus receptorbinding domain complexed with its murine receptor. Proc Natl Acad Sci USA 2011; 108: 10696-10701.
42. He Y, Lu H, Siddiqui P et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005; 174: 4908-4915.
43. Gui M, Song W, Zhou H et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res 2017; 27: 119-129.
44. Robinson JE, Hastie KM, Cross RW et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 2016; 7: 11544.
45. Blattner C, Lee JH, Sliepen K et al. Structural delineation of a quaternary, cleavagedependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014; 40: 669-680.
46. King AM, Adams MJ, Lefkowitz EJ. Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier, Netherland, 2011; 9: 193-210.
47. Deng F, Ye G, Liu Q et al. Identification and comparison of receptor binding characteristics of the spike protein of two porcine epidemic diarrhea virus strains. Viruses 2016; 8: 55.
48. Schultze B, Krempl C, Ballesteros ML et al. Transmissible gastroenteritis coronavirus, but not the related porcine respiratory coronavirus, has a sialic acid (N-glycolylneuraminic acid) binding activity. J Virol 1996; 70: 5634-5637.
49. Modjarrad K. MERS-CoV vaccine candidates in development: The current landscape. Vaccine 2016; 34: 2982-2987.
50. Du L, Jiang S. Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther 2015; 15: 1647-1651.